ANIK

14.95

2.75% 0.40

Handel nachbörslich: 14.95

Anika Therapeutics Inc (ANIK)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$14.55

Offen:

$14.57

24-Stunden-Volumen:

96,293

Relative Volume:

0.66

Marktkapitalisierung:

$198.92M

Einnahmen:

$116.26M

Nettoeinkommen (Verlust:

$-11.08M

KGV:

-18.88

EPS:

-0.7917

Netto-Cashflow:

$1.04M

1W Leistung:

-2.03%

1M Leistung:

+1.01%

6M Leistung:

+51.78%

1J Leistung:

+3.17%

1-Tages-Spanne:

$14.57

$15.18

1-Wochen-Bereich:

$11.92

$15.69

52-Wochen-Spanne:

$7.8701

$16.24

Anika Therapeutics Inc Stock (ANIK) Company Profile

Firmenname

Anika Therapeutics Inc

Sektor

Healthcare (1106)

Branche

Drug Manufacturers - Specialty & Generic (84)

Telefon

(781) 457-9000

Adresse

32 WIGGINS AVENUE, BEDFORD, MA

Mitarbeiter

235

Twitter

Nächster Verdiensttermin

2026-04-29

Neueste SEC-Einreichungen

ANIK's Discussions on Twitter

Compare ANIK vs TAK, ZTS, TEVA, HLN, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANIK Anika Therapeutics Inc	14.95	193.60M	116.26M	-11.08M	1.04M	-0.7917
TAK Takeda Pharmaceutical Co Adr	16.55	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.67B	3.18B	1.33B	1.04B	27.90

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-17	Eingeleitet	B. Riley Securities	Buy
2024-11-01	Bestätigt	Barrington Research	Outperform
2023-08-14	Hochstufung	Barrington Research	Mkt Perform → Outperform
2023-03-07	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-11-09	Hochstufung	Barrington Research	Mkt Perform → Outperform
2022-10-14	Fortgesetzt	Stephens	Equal-Weight
2022-03-09	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-03-09	Herabstufung	Stephens	Overweight → Equal-Weight
2021-11-16	Eingeleitet	Stephens	Overweight
2021-07-16	Eingeleitet	UBS	Neutral
2020-12-16	Hochstufung	Barrington Research	Mkt Perform → Outperform
2020-05-08	Herabstufung	Barrington Research	Outperform → Mkt Perform
2020-01-21	Hochstufung	Sidoti	Neutral → Buy
2020-01-10	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2019-11-05	Eingeleitet	BWS Financial	Sell
2019-09-24	Bestätigt	Barrington Research	Outperform
2019-09-23	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-07-25	Hochstufung	First Analysis Sec	Neutral → Strong Buy
2019-02-22	Herabstufung	First Analysis Sec	Outperform → Neutral
2019-02-22	Herabstufung	Sidoti	Buy → Neutral
2018-07-27	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-06-20	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-06-20	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2018-05-04	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-02-23	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-01-24	Hochstufung	First Analysis Sec	Equal-Weight → Overweight
2017-10-27	Bestätigt	Barrington Research	Outperform
2016-05-09	Hochstufung	Singular Research	BUY - Long-Term → Buy
2016-04-27	Herabstufung	Northland Capital	Outperform → Market Perform
2016-02-26	Bestätigt	Barrington Research	Outperform

Alle ansehen

Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten

May 05, 2026

Insider Buying: HENNEMAN JOHN B III Acquires 5,000 Shares of Ani - GuruFocus

May 05, 2026

Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work - MSN

May 05, 2026

Anika Therapeutics Q1 2026 earnings preview - MSN

May 05, 2026

May 04, 2026

Anika Therapeutics director John Henneman buys $73,319 in shares By Investing.com - Investing.com Canada

May 04, 2026

Anika Therapeutics director John Henneman buys $73,319 in shares - Investing.com

May 04, 2026

Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy - Stock Titan

May 04, 2026

May 03, 2026

President of Anika Therapeutics Picks Up 51% More Stock - Yahoo Finance

May 03, 2026

May 02, 2026

Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat

May 02, 2026

May 01, 2026

ANIK | Anika Therapeutics Inc Insider Trading - Quiver Quantitative

May 01, 2026

Anika Therapeutics Projects $114 Million Revenue Growth for Fiscal 2026 - HarianBasis.co

May 01, 2026

Apr 30, 2026

Insider Buying: Stephen Griffin Acquires Shares of Anika Therape - GuruFocus

Apr 30, 2026

Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock - MarketBeat

Apr 30, 2026

Anika Therapeutics Q1 2026 Financial Results: Revenue, Losses, and Key Financial Statements Overview - Minichart

Apr 30, 2026

Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock By Investing.com - Investing.com India

Apr 30, 2026

Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock - Investing.com

Apr 30, 2026

Insider Purchase: President and CEO of $ANIK Buys 12,200 Shares - Quiver Quantitative

Apr 30, 2026

Anika Therapeutics (ANIK) CEO buys 12,200 shares in open market - Stock Titan

Apr 30, 2026

Anika Therapeutics : 2026 Proxy Statement - marketscreener.com

Apr 30, 2026

Bullish On Anika Therapeutics’s Pullback As Integrity Scales (NASDAQ:ANIK) - Seeking Alpha

Apr 30, 2026

Rotator cuff procedure advances driven by biology, Anika Therapeutics claims - Traders Union

Apr 30, 2026

(ANIK) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 30, 2026

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 30, 2026

Revenue climbs 13% as Anika Therapeutics (NASDAQ: ANIK) boosts margins but stays in loss - Stock Titan

Apr 30, 2026